P2RY12 and diabetes mellitus: Targeting the ADP-activated P2Y12 pathway effectively reduces MPA in several clinical studies: In patients with acute MI, atherosclerotic vascular disease, and cardiovascular risk factors including diabetes mellitus, intake of P2Y12 inhibitor therapy was associated with MPA reduction in vivo and ex vivo (73, 75, 143, 144).